Carisoprodol-Mediated Modulation of GABAA Receptors: In Vitro and in Vivo Studies
Authors:
- Michael B. GatchMGMichael B. Gatch
- Cynthia M. TaylorCTCynthia M. Taylor
- Cathy L. Bell-HornerCBCathy L. Bell-Horner
- Michael J. ForsterMFMichael J. Forster
- Glenn H. DillonGDGlenn H. Dillon
- 1 May 2009
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 329 (2) , 827-837
Abstract
Carisoprodol is a frequently prescribed muscle relaxant. In recent years, this drug has been increasingly abused. The effects of carisoprodol have been attributed to its metabolite, meprobamate, a controlled substance that produces sedation via GABAA receptors (GABAARs). Given the structural similarities between carisoprodol and meprobamate, we used electrophysiological and behavioral approaches to investigate whether carisoprodol directly affects GABAAR function. In whole-cell patch-clamp studies, carisoprodol allosterically modulated and directly activated human α1β2γ2 GABAAR function in a barbiturate-like manner. At millimolar concentrations, inhibitory effects were apparent. Similar allosteric effects were not observed for homomeric ρ1 GABA or glycine α1 receptors. In the absence of GABA, carisoprodol produced picrotoxin-sensitive, inward currents that were significantly larger than those produced by meprobamate, suggesting carisoprodol may directly produce GABAergic effects in vivo. When administered to mice via intraperitoneal or oral routes, carisoprodol elicited locomotor depression within 8 to 12 min after injection. Intraperitoneal administration of meprobamate depressed locomotor activity in the same time frame. In drug discrimination studies with carisoprodol-trained rats, the GABAergic ligands pentobarbital, chlordiazepoxide, and meprobamate each substituted for carisoprodol in a dose-dependent manner. In accordance with findings in vitro, the discriminative stimulus effects of carisoprodol were antagonized by a barbiturate antagonist, bemegride, but not by the benzodiazepine site antagonist, flumazenil. The results of our studies in vivo and in vitro collectively suggest the barbiturate-like effects of carisoprodol may not be due solely to its metabolite, meprobamate. Furthermore, the functional traits we have identified probably contribute to the abuse potential of carisoprodol.Keywords
This publication has 37 references indexed in Scilit:
- Carisoprodol Intoxications and Serotonergic FeaturesClinical Toxicology, 2005
- Impairment due to intake of carisoprodolDrug and Alcohol Dependence, 2004
- Enantioselectivity of α-Benzyl-α-methyl-γ-butyrolactone-Mediated Modulation of Anticonvulsant Activity and GABAA Receptor FunctionThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Formation of meprobamate from carisoprodol is catalysed byCYP2C19Pharmacogenetics, 1996
- Carisoprodol Elimination in HumansTherapeutic Drug Monitoring, 1994
- Carisoprodol (Soma): A New and Cautious Perspective on an Old AgentSouthern Medical Journal, 1993
- Differential interactions between chlordiazepoxide, pentobarbital and benzodiazepine antagonists Ro 15-1788 and CGS 8216 in a drug discrimination procedurePharmacology Biochemistry and Behavior, 1986
- Ro 15-1788 antagonizes the discriminative stimulus effects of diazepam in rats but not similar effects of pentobarbitalLife Sciences, 1982
- Carisoprodol Dependence: A Case ReportThe American Journal of Drug and Alcohol Abuse, 1978
- METABOLISM OF DRUGS IN OLD RATS (II) METABOLISM IN VIVO AND EFFECT OF DRUGS IN OLD RATSThe Japanese Journal of Pharmacology, 1968